{"entity":{"id":"epipangi-dx","kind":"drug","name":"EpiPanGI Dx","aka":[],"tldr":"A research blood test that looks for six digestive-system cancers at once and predicts which organ the signal comes from.","summary":"Kandimalla et al. (Clinical Cancer Research 2021) validated the panel in 300 cell-free DNA specimens: a pan-gastrointestinal panel detected all six cancers (colorectal, hepatocellular, oesophageal squamous and adenocarcinoma, gastric, pancreatic) with an area under the curve of 0.88, and the EpiPanGI Dx tissue-of-origin panel predicted the organ with accuracy of 0.85 to 0.95 for most. It is an academic assay without regulatory status.","status":"emerging","asOf":"2026-10-29","links":[{"label":"Kandimalla et al., Clinical Cancer Research 2021","url":"https://doi.org/10.1158/1078-0432.CCR-21-1982"}],"tags":["test","mced","evidence:insufficient"],"related":[],"cancers":["colorectal","hcc","gastric","esophageal","pancreatic"],"sections":[],"technologies":["mced","liquid-biopsy","cfdna-methylation-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-epipangi-dx-clin-cancer-res-2021"],"journals":[],"dependsOn":[],"notes":["Evidence grade insufficient for the claim that taking this test reduces late-stage diagnosis or cancer deaths: no randomised trial of it has reported either outcome, and its published performance comes from case-control or single-arm studies. The only randomised result for any multi-cancer test, NHS-Galleri, did not show fewer stage III or IV cancers.","What a result means: a positive result is a reason for further tests, not a diagnosis; a negative result does not rule cancer out and does not replace the screening tests that have been shown to work (bowel, breast, cervical and, where eligible, lung screening)."],"brand":"EpiPanGI Dx","modality":"Gastrointestinal multi-cancer blood test, academic research assay (cell-free DNA methylation)","mechanism":"Targeted bisulphite sequencing of 67,832 methylated regions chosen from tumour tissue, with panels to detect any digestive cancer and to predict which organ it is in.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/epipangi-dx/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cfdna-methylation-testing","kind":"technology","name":"Cell-free DNA methylation tests","route":"/technologies/cfdna-methylation-testing/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"}],"institution":[{"id":"city-of-hope","kind":"institution","name":"City of Hope","route":"/institutions/city-of-hope/"}],"paper":[{"id":"paper-epipangi-dx-clin-cancer-res-2021","kind":"paper","name":"EpiPanGI Dx: A Cell-free DNA Methylation Fingerprint for the Early Detection of Gastrointestinal Cancers","route":"/key-papers/paper-epipangi-dx-clin-cancer-res-2021/"}]}}